Oksiuta Marzanna, Matuszczak Ewa, Dębek Wojciech, Dzienis-Koronkiewicz Ewa, Hermanowicz Adam, Tylicka Marzena
Pediatric Surgery Department, Medical University of Bialystok, Poland.
Postepy Hig Med Dosw (Online). 2014 Sep 12;68:1138-44. doi: 10.5604/17322693.1120990.
Infantile hemangiomas (IH) are neoplastic proliferations of endothelial cells which occur with an incidence of 10 to 12% within the first year of life. IH grow after birth and usually regress spontaneously, but still can lead to deformities when they are located in the facial areas of the lip, eyelid, nasal tip or the ear. We wanted to share our experience in the treatment of problematic IH with propranolol. A retrospective review of medical charts was performed for 40 consecutive children treated with propranolol because of problematic IH between 2009 and 2012. 40 patients (33 girls, 7 boys) with a median age of 4.2 months (aged 1 to 11 months) were treated because of problematic IH. Rapid improvement was reported in the first days of treatment in 38 patients. In one case we had to terminate the treatment because serious tachycardia developed within the first 48 hours after propranolol was started. In this case the patient benefited from alternative treatment with timolol maleate gel. 35 patients (87%) showed an excellent response with complete resolution of the lesion. 4 patients (10%) showed a good result with >50% reduction in the size of the hemangioma. Also a patient with residual IH after terminating oral propranolol benefited from topical treatment with timolol maleate gel. A minor side effect was poor weight gain during prolonged treatment in one patient and tachycardia in another patient in which case we had to terminate the treatment.
Our observations show that gradually increasing the dosage of propranolol up to 3 mg/kg and gradually weaning the dosage is safe and effective in treatment of problematic IH. Timolol maleate gel should be considered as a complementary treatment for residual hemangiomas after terminating propranolol treatment or as an alternative treatment in patients who do not tolerate oral propranolol well.
婴儿血管瘤(IH)是内皮细胞的肿瘤性增殖,在出生后第一年内的发病率为10%至12%。IH在出生后生长,通常会自发消退,但当位于嘴唇、眼睑、鼻尖或耳朵等面部区域时,仍可导致畸形。我们想分享我们用普萘洛尔治疗有问题的IH的经验。对2009年至2012年间因有问题的IH而连续接受普萘洛尔治疗的40名儿童的病历进行了回顾性分析。40例患者(33例女孩,7例男孩)因有问题的IH接受治疗,中位年龄为4.2个月(年龄1至11个月)。38例患者在治疗的头几天报告有快速改善。有1例在开始使用普萘洛尔后的48小时内出现严重心动过速,我们不得不终止治疗。在这种情况下,患者受益于用马来酸噻吗洛尔凝胶的替代治疗。35例患者(87%)显示出极佳的反应,病变完全消退。4例患者(10%)显示出良好的效果,血管瘤大小缩小>50%。还有1例在停用口服普萘洛尔后有残余IH的患者,受益于用马来酸噻吗洛尔凝胶的局部治疗。1例患者在长期治疗期间体重增加不佳,另1例患者出现心动过速,在这种情况下我们不得不终止治疗,这是轻微的副作用。
我们的观察表明,将普萘洛尔剂量逐渐增加至3mg/kg并逐渐减量,在治疗有问题的IH时是安全有效的。马来酸噻吗洛尔凝胶应被视为普萘洛尔治疗终止后残余血管瘤的补充治疗,或作为不能很好耐受口服普萘洛尔的患者的替代治疗。